Imunon, Inc. (IMNN) has a very important June 2025 planned with multiple presentations at prestigious scientific conferences and the publication of the full data set from the OVATION 2 trial. On June 3, 2025, Dr. Premal Thaker will present updated results from the Phase 1/2 OVATION 2 trial, which includes data showing a median increase in overall survival of 13 months for patients treated with IMNN-001 plus standard of care compared to those just receiving standard of care (HR = 0.69). Later in June, Dr. Thaker will be presenting immune biomarker data from the OVATION 2 trial at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025. Simultaneously with the ASCO presentation, the full results from the OVATION 2 trial will be published in the peer-reviewed journal Gynecologic Oncology. These activities show the scientific communities overwhelmingly positive response to these data and provide positive momentum for the company as it initiates the Phase 3 OVATION 3 trial.
